Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?

Table 1 Clinical studies of second-line gemcitabine-containing regimens

Ref.	Regimen	Sample size	RR1	PFS/TTP (mo)	Med OS (mo)	1 yr survival
Kozuch et al[4], 2001	G-FLIP	34	24%	3.9	10.3	47%
Reni et al[6], 2008	PEFG	46	24%	5.0	8.3	26%
Demols et al[9], 2006	GEMOX	33	21%	4.2	6.0	NR
Fortune et al[76], 2009	GEMOX	17	24%	2.6	6.4	29%
Stathopoulos et al[77], 2006	Gem, Lipoplatin	24	8.3%	NR	4.0	NR
Tschoep et al[11], 2013	Gem, Cisplatin, RHT	23	4.3%	4.3	NR	NR
Morizane et al[12], 2012	Gem, S-1	40	18%	2.8	7.0	18%
Ernani et al[13], 2012	Gem, nab-Paclitaxel	10	20%	3.2	NR	NR

¹Intent-to-treat analysis. G-FLIP: Gemcitabine, 5-fluorouracil, leucovorin, cisplatin; PEFG: Cisplatin, epirubicin, 5-fluorouracil, gemcitabine; GEMOX: Gemcitabine, oxaliplatin; Gem: Gemcitabine; RHT: Regional hyperthermia; Nab-paclitaxel: Albumin-bound nanoparticle paclitaxel; NR: Not reported; PFS: progression free survival; OS: Overall survival; TTP: Time to progression.